Communiqués de presse – 2011
- 9 novembre 2011
Alethia Biotherapeutics announces promising in vivo results for its EMT inhibitor AB-16B5 and issuance of a patent for the role of secreted clusterin in EMT
Alethia Biotherapeutics announces promising in vivo results for its EMT inhibitor AB-16B5 and issuance of a patent for the role of secreted clusterin in EMT